Alexander J Rajic1, Peter S Pressman2, Jonathan H Woodcock3, Heidi J Chial4, Christopher M Filley5. 1. University of Colorado, Anschutz Medical Campus, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America. 2. University of Colorado, Anschutz Medical Campus, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Behavioral Neurology Section, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, University of Colorado Alzheimer's and Cognition Center, Mail Stop F429, Building 400, 12469 East 17th Place, Aurora, CO 80045, United States of America. Electronic address: peter.pressman@cuanschutz.edu. 3. University of Colorado, Anschutz Medical Campus, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Behavioral Neurology Section, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, University of Colorado Alzheimer's and Cognition Center, Mail Stop F429, Building 400, 12469 East 17th Place, Aurora, CO 80045, United States of America. 4. University of Colorado, Anschutz Medical Campus, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, University of Colorado Alzheimer's and Cognition Center, Mail Stop F429, Building 400, 12469 East 17th Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Linda Crnic Institute for Down Syndrome, 12700 E. 19th Ave., Mail Stop 8608, Aurora, CO 80045, United States of America. 5. University of Colorado, Anschutz Medical Campus, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Department of Psychiatry, 13001 East 17(th) Place, Q20-C2000, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Behavioral Neurology Section, Department of Neurology, 12469 East 17(th) Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, University of Colorado Alzheimer's and Cognition Center, Mail Stop F429, Building 400, 12469 East 17th Place, Aurora, CO 80045, United States of America; University of Colorado, Anschutz Medical Campus, Marcus Institute for Brain Health, 12348 E Montview Blvd., Aurora, CO 80045, United States of America.
Abstract
INTRODUCTION: Our objective was to determine whether non-standardized testing of olfaction may provide useful information for predicting cognitive dysfunction and decline in patients with neurobehavioral disorders. METHODS: We conducted cross-sectional and longitudinal analyses of 82 patients who presented to a Memory Clinic with a chief complaint of cognitive deficits using non-standardized odor identification testing (nSOIT). Each patient was classified as having intact or impaired olfaction based on the ability to identify and name the odor of coffee grounds. The cross-sectional study used Student's t-test to examine whether nSOIT results were related to cognitive dysfunction as approximated by Montreal Cognitive Assessment (MoCA) scores. The longitudinal study used mixed effects multiple regression with an interaction term to investigate whether nSOIT results were predictive of cognitive decline over a period of follow-up testing (0.4 to 4.0 years [mean 1.4, SD 0.8]) to compare patients who exhibited cognitive decline over the evaluation period (decliners) and those who did not (non-decliners). RESULTS: Analysis of the initial use of nSOIT in the cross-sectional study demonstrated no association between nSOIT performance and objective cognitive dysfunction. In the longitudinal study, impairment in follow-up nSOIT testing was found to be a sensitive but nonspecific predictor of cognitive decline. CONCLUSION: These results suggest that routine olfactory testing may serve as a convenient and readily available method that can be used by clinicians to better predict cognitive dysfunction and decline in patients with a variety of neurobehavioral disorders.
INTRODUCTION: Our objective was to determine whether non-standardized testing of olfaction may provide useful information for predicting cognitive dysfunction and decline in patients with neurobehavioral disorders. METHODS: We conducted cross-sectional and longitudinal analyses of 82 patients who presented to a Memory Clinic with a chief complaint of cognitive deficits using non-standardized odor identification testing (nSOIT). Each patient was classified as having intact or impaired olfaction based on the ability to identify and name the odor of coffee grounds. The cross-sectional study used Student's t-test to examine whether nSOIT results were related to cognitive dysfunction as approximated by Montreal Cognitive Assessment (MoCA) scores. The longitudinal study used mixed effects multiple regression with an interaction term to investigate whether nSOIT results were predictive of cognitive decline over a period of follow-up testing (0.4 to 4.0 years [mean 1.4, SD 0.8]) to compare patients who exhibited cognitive decline over the evaluation period (decliners) and those who did not (non-decliners). RESULTS: Analysis of the initial use of nSOIT in the cross-sectional study demonstrated no association between nSOIT performance and objective cognitive dysfunction. In the longitudinal study, impairment in follow-up nSOIT testing was found to be a sensitive but nonspecific predictor of cognitive decline. CONCLUSION: These results suggest that routine olfactory testing may serve as a convenient and readily available method that can be used by clinicians to better predict cognitive dysfunction and decline in patients with a variety of neurobehavioral disorders.
Authors: Matthew R Woodward; Chaitanya V Amrutkar; Harshit C Shah; Ralph H B Benedict; Sanjanaa Rajakrishnan; Rachelle S Doody; Li Yan; Kinga Szigeti Journal: Neurol Clin Pract Date: 2017-02
Authors: Dara R Adams; David W Kern; Kristen E Wroblewski; Martha K McClintock; William Dale; Jayant M Pinto Journal: J Am Geriatr Soc Date: 2017-09-25 Impact factor: 5.562
Authors: Hana Magerova; Martin Vyhnalek; Jan Laczo; Ross Andel; Irena Rektorova; Alexandra Kadlecova; Martin Bojar; Jakub Hort Journal: Am J Alzheimers Dis Other Demen Date: 2014-06-16 Impact factor: 2.035
Authors: Rosebud O Roberts; Teresa J H Christianson; Walter K Kremers; Michelle M Mielke; Mary M Machulda; Maria Vassilaki; Rabe E Alhurani; Yonas E Geda; David S Knopman; Ronald C Petersen Journal: JAMA Neurol Date: 2016-01 Impact factor: 18.302
Authors: Swaantje Casjens; Angelika Eckert; Dirk Woitalla; Gisa Ellrichmann; Michael Turewicz; Christian Stephan; Martin Eisenacher; Caroline May; Helmut E Meyer; Thomas Brüning; Beate Pesch Journal: PLoS One Date: 2013-05-16 Impact factor: 3.240